<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045015</url>
  </required_header>
  <id_info>
    <org_study_id>Liquorice_Saliva_01</org_study_id>
    <nct_id>NCT04045015</nct_id>
  </id_info>
  <brief_title>Liquorice and Salivary Cortisol</brief_title>
  <official_title>Effects of Liquorice on Salivary Cortisol and Cortisone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Salivary cortisol is used as a diagnostic analysis in the investigation of suspected
      Cushings' syndrome. This study evaluates if liqourice intake increases salivary cortisol in
      healthy individuals. Late night salivary cortisol and cortisone is analysed before, during
      and after 7 days of liqourice intake in three different doses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each group of 10 individuals uses liqourice for 7 days and late night salivary cortisol and cortisone is analysed before (baseline), during and after (washout) intake.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late night salivary cortisol</measure>
    <time_frame>day 1 to day 7 during liqourice intake</time_frame>
    <description>Significantly increased salivary cortisol 23:00 PM compared to baseline (i.e. before start of liqourice intake).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to normalization of late night salivary cortisol</measure>
    <time_frame>1-28 days efter liqourice intake is stopped</time_frame>
    <description>Time from liqourice intake is stopped until significant increase of late night salivary cortisol from baseline (i.e. assuming outcome 1 is significant increase) is no longer significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morning salivary cortisol</measure>
    <time_frame>day 1-2 during liqourice intake</time_frame>
    <description>Significantly increased salivary cortisol 08:00 AM compared to baseline (i.e. before start of liqourice intake).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late night salivary cortisol/cortisone ratio</measure>
    <time_frame>day 1 to day 7 during liqourice intake</time_frame>
    <description>Significantly increased salivary cortisol 23:00 PM compared to baseline (i.e. before start of liqourice intake).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normalization of late night salivary cortisol/cortisone ratio</measure>
    <time_frame>1-28 days efter liqourice intake is stopped</time_frame>
    <description>Time from liqourice intake is stopped until significant increase of late night salivary cortisol from baseline (i.e. assuming outcome 1 is significant increase) is no longer significant.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cushing Syndrome</condition>
  <condition>Hypercortisolism</condition>
  <arm_group>
    <arm_group_label>glycyrrhizic acid 1.5 mg/kg body weight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liqourice corresponding to 1.5 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glycyrrhizic acid 3.0 mg/kg body weight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liqourice corresponding to 3.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glycyrrhizic acid 6.0 mg/kg body weight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liqourice corresponding to 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Liqourice</intervention_name>
    <description>Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.</description>
    <arm_group_label>glycyrrhizic acid 1.5 mg/kg body weight</arm_group_label>
    <arm_group_label>glycyrrhizic acid 3.0 mg/kg body weight</arm_group_label>
    <arm_group_label>glycyrrhizic acid 6.0 mg/kg body weight</arm_group_label>
    <other_name>glycyrrhizic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18-65 years.

        Exclusion Criteria:

          -  Known pituitary or adrenal disease

          -  Medication with glucocorticoids (incl. inhalation, nasal, dermal)

          -  Known hypertension or blood pressure &gt;140/90 at screening

          -  tobacco use

          -  Subjective problems in oral mucosa or saliva

          -  Abnormal diurnal rhythm (awake 03:00 - 05:30)

          -  Difficulties taking liqourice for 3 weeks or refraining from liqourice during 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Dahlqvist, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per Dahlqvist, MD, PhD</last_name>
    <phone>+46-907853390</phone>
    <email>per.dahlqvist@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nils Bäcklund, MD</last_name>
    <phone>+46-907850000</phone>
    <email>nils.backlund@umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Public Health and Clinical, Umeå University</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Dahlqvist, MD, PhD</last_name>
      <phone>+46-907853390</phone>
      <email>per.dahlqvist@umu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Nieman LK. Cushing's syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015 Oct;173(4):M33-8. doi: 10.1530/EJE-15-0464. Epub 2015 Jul 8. Review.</citation>
    <PMID>26156970</PMID>
  </results_reference>
  <results_reference>
    <citation>Perogamvros I, Ray DW, Trainer PJ. Regulation of cortisol bioavailability--effects on hormone measurement and action. Nat Rev Endocrinol. 2012 Dec;8(12):717-27. doi: 10.1038/nrendo.2012.134. Epub 2012 Aug 14. Review.</citation>
    <PMID>22890008</PMID>
  </results_reference>
  <results_reference>
    <citation>Whorwood CB, Sheppard MC, Stewart PM. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology. 1993 Jun;132(6):2287-92.</citation>
    <PMID>8504732</PMID>
  </results_reference>
  <results_reference>
    <citation>Perogamvros I, Owen LJ, Newell-Price J, Ray DW, Trainer PJ, Keevil BG. Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3771-5. doi: 10.1016/j.jchromb.2009.09.014. Epub 2009 Sep 18.</citation>
    <PMID>19783236</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umeå University</investigator_affiliation>
    <investigator_full_name>Per Dahlqvist</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycyrrhizic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

